NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Live Oak Bancshares, Inc. ("Live Oak" or the "Company") (NYSE:LOB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Live Oak and certain of […]
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ:BCYC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Bicycle and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Owens Corning ("Owens Corning" or the "Company") (NYSE:OC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Owens Corning and certain of its officers
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. ("agilon" or the "Company") (NYSE:AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether agilon and certain of its officers and/or
NEW YORK, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Enphase Energy, Inc. ("Enphase" or the "Company") (NASDAQ:ENPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Enphase and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Intellia and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Tvardi and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Coty, Inc. ("Coty" or the "Company") (NYSE:COTY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Coty and certain of its officers and/or directors
Zavation Medical Products, LLC (“Zavation”), a leading innovator in spinal device technology, announces the first successful implantations of the Varisync® ALIF NanoPrime™ System, a next-generation stand-alone ALIF system featuring Zavation's proprietary titanium ion bond technology. https://mma.prnewswire.com/media/2823713/Varisync_ALIF_Construct_with_NanoPrime_Cage.jpg NanoPrime™ combines the mechanical advantages of PEEK with the biological benefits of titanium, providing enhanced radiographic visualization, biomechanical compatibility5,
NEW YORK CITY, NY / ACCESS Newswire / November 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Alvotech and certain of its officers and/or directors have